drugset / Trial / NCT06660290
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
RandomizedCrossoverSingle-blindTreatment
Summary
The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).
Timeline
- Start
- 2025-01-15
- Primary completion
- 2025-02-06
- Completion
- 2025-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acoltremon | Small molecule | 0.003 % | Topical |